Innovation
TargED Announces First Patient Successfully Dosed in Study of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura
Subcutaneous delivery is most effective for insulin and other therapeutic polypeptides, including GLP-1 receptor agonists, but pain, angioedema, anaphylaxis, lipodystrophy and neuropathy can complicate treatment. Inconvenience, social distress and injection phobia may undermine adherence, driving interest in non-invasive alternatives. S.L.I.M.® sublingual technology offers a potential needle-free approach.

Insulin transformed type 1 diabetes (T1D) from rapidly fatal to treatable. In 1921, Frederick Banting and Charles Best obtained a glucose-lowering pancreatic extract in John Macleod’s Toronto laboratory. James Collip’s purification enabled Leonard Thompson’s treatment in January 1922, followed by industrial production in North America and Europe.
Insulin remains predominantly subcutaneous, despite delivery evolving from glass syringes to disposable syringes, pens, pumps and increasingly automated systems.
Drawbacks
Subcutaneous insulin’s drawbacks include hypoglycaemia, weight gain, injection pain, lipohypertrophy, hypersensitivity reactions, including angioedema and anaphylaxis, oedema, treatment-induced neuropathy and transient refractive changes. Inconvenience, social distress and injection phobia can undermine adherence. Despite continual glucose monitoring and treatment and lifestyle adjustments, many with T1D lack sustained glycaemic control. Injection supplies generate metal and plastic waste. Diabetes affected 589 million adults in 2024, with 853 million projected by 2050. T1D affected approximately 8.4 million people in 2021, with 13.5–17.4 million projected by 2040. These burdens highlight the need for alternative delivery.
Non-invasive delivery
Non-invasive insulin delivery remains an unmet need. Gastrointestinal degradation, poor intestinal permeability and hepatic first-pass effects limit oral bioavailability. Oral insulin I338 matched injected glargine’s fasting glucose control in phase 2, but high doses made commercial development unviable. Nasal and pulmonary routes have also been explored. Inhaled Exubera was withdrawn in 2007 over commercial, cost and pulmonary-safety concerns. Afrezza lowers HbA1c but can cause transient cough and a small decline in expiratory capacity; it is contraindicated in smokers and patients with chronic lung disease.
Dutch company SUBLIN BV, founded in 2018 as a spin-out of NanoServe BV’s healthcare branch, developed S.L.I.M.® (sublingual insulin modality). Its patented nano- and microparticles encapsulate small and large molecules, including insulin, insulin analogues and GLP-1 analogues, for release into the bloodstream after crossing the sublingual mucosa. Manufacturing is designed for simplicity, reproducibility and cost-effective scale-up.
Formulations
Slow- and rapid-release S.L.I.M.® formulations include submicron particles produced, characterised and tested preclinically. Reproducible particle size and insulin loading of 0.2–12 IU/mg preserve insulin’s native structure. For clinical use, a biodegradable film incorporates particles containing a defined insulin or insulin-analogue dose.

From pigs to human clinical trial
In healthy domestic pigs, subcutaneous insulin-loaded S.L.I.M.® particles produced glucose responses comparable to NovoRapid ®, demonstrating in vivo efficacy. Safety was demonstrated in several animal models, including pigs. Sublingual delivery lowered glucose by approximately 3 mmol/L within 30 minutes (1 mmol/L per 10 minutes). Slow- and rapid-release formulations were developed, including a biomimetic formulation that releases insulin in response to rising glucose.
In streptozotocin-induced diabetic pigs, once-daily insulin-loaded S.L.I.M.® particles increased blood insulin after feeding and rapidly lowered glucose. This response recurred after a second feeding without reapplication and persisted the following day. Insulin pharmacokinetics resembled those following subcutaneous injections in patients with diabetes, with improved glycaemic control in pigs. Two phase I/II trials in adults with T1D (n=20) are evaluating the particles, with initial results expected in the first quarter of 2027. If safety and sustained release are confirmed, this approach could advance needle-free delivery that more closely mimics physiological β-cell secretion.
Incretins and obesity
Most therapeutic peptides require injections despite oral permeation enhancers and protease inhibitors. Liraglutide, semaglutide and dual GLP-1/GIP agonist tirzepatide expanded from type 2 diabetes to weight management. Oral semaglutide gained weight-management approval in December 2025; non-peptide agonist orforglipron followed in April 2026. These approaches are difficult to transfer to insulin, whose narrow therapeutic index requires precise dosing and consistent bioavailability. Sublin’s S.L.I.M.®-encapsulated GLP-1 receptor agonists showed favourable safety and high bioavailability after one sublingual dose in pigs, suggesting convenient delivery and prolonged uptake.
This approach could benefit insulin users and 2.11 billion adults with overweight or obesity, for whom GLP-1 or dual GLP-1/GIP agonists are increasingly indicated.
Conclusion
S.L.I.M. ® particles offer a potential needle-free alternative for therapeutic polypeptides. Following promising preclinical results, phase I/II trials are evaluating safety and efficacy in humans. Sublin seeks pharmaceutical partners to support further development and commercialisation. S.L.I.M. ® particles require no cooling, enabling prolonged storage and transport at room temperature.